Novo Nordisk has shared positive headline results from a late-stage study evaluating a higher dose of its GLP-1 receptor ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...

Novo Nordisk markets its semaglutide medicines as Ozempic pre-filled pens and Rybelsus ... subcutaneous semaglutide 7.2 mg compared with Wegovy and placebo in adults with obesity.

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of ...

Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly ...

Ozempic came out with a higher-strength, 2 mg dose that was not approved until after this trial was over. Considering GLP-1 agonists tend to perform better at higher doses, it remains to be seen ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

Drugs like Ozempic and Wegovy, called GLP-1 agonists, carry more benefits than risks when taken for their approved uses, according to a comprehensive analysis of their effects on 175 conditions.

WASHINGTON (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and ...

Drugs like Ozempic and Wegovy were already off to fast starts because of their ability to help treat Type 2 diabetes and improve weight loss for millions of Americans. But a new study suggests ...